Medicine and Dentistry
Krukenberg Tumor
100%
Neoplasm
83%
Breast Cancer
74%
Ovarian Cancer
49%
Immunohistochemistry
32%
Messenger RNA
31%
Prognostic Factor
30%
Uterine Cancer
30%
In Vitro
27%
Protein Expression
24%
Hazard Ratio
22%
Carcinoma
21%
Colorectal Carcinoma
21%
Biological Marker
21%
Endometrium Carcinoma
21%
Overall Survival
19%
Cyclooxygenase 2
19%
Malignant Neoplasm
18%
Endometriosis
18%
Breast Carcinoma
17%
Formaldehyde
16%
Estrogen Receptor
16%
Epidermal Growth Factor Receptor 2
16%
Metastatic Carcinoma
15%
Gamma Urogastrone
15%
Cancer Cell
14%
Hormone Receptor
14%
Biopsy Technique
13%
ELAV Like Protein 1
13%
Histone Deacetylase
13%
Melanoma
13%
In Situ Hybridization
12%
Receptor Expression
12%
Cell Proliferation
11%
Protein P53
11%
Pathologist
10%
Diseases
10%
Lymph Node
10%
Next Generation Sequencing
10%
Colon Carcinoma
10%
Endometrium
10%
Risk Stratification
9%
Tissue Microarray
9%
Epidermal Growth Factor Receptor
9%
Cancer Staging
9%
Primary Tumor
9%
Gene Expression
9%
Guanine Nucleotide Binding Protein
9%
Mammalian Target of Rapamycin
9%
Carisoprodol
9%
Keyphrases
Breast Cancer
58%
Ovarian Carcinoma
48%
Tumor
36%
Immunohistochemistry
33%
Ovarian Cancer
32%
Prognostic Impact
30%
Endometrial Cancer
29%
Human Epidermal Growth Factor Receptor 2 (HER2)
29%
Epithelial Ovarian Cancer
28%
Cyclooxygenase-2
27%
Overall Survival
26%
Triple-negative Breast Cancer
26%
Prognostic Factors
25%
Overexpression
24%
Protein Expression
22%
Endometriosis
22%
Carcinoma
22%
Expression Pattern
22%
Formalin-fixed Paraffin-embedded Tissue
19%
Hazard Ratio
18%
Polo-like Kinase 1 (PLK1)
18%
EndoPredict
18%
Programmed Death-ligand 1 (PD-L1)
18%
Ovarian Cancer Cells
17%
In Situ Hybridization
16%
Core Needle Biopsy
16%
MRNA Expression
15%
Colorectal Cancer
15%
Human Ovarian Carcinoma
15%
Hormone Receptor-positive
14%
Tumor Grade
14%
MRNA Level
14%
DNA Methylation (DNAm)
13%
Sporadic Colorectal Cancer
13%
PITX2
13%
Mammalian Target of Rapamycin (mTOR)
13%
GPER1
13%
Metastasis
13%
Tumor-infiltrating Lymphocytes
12%
Histone Deacetylase 1 (HDAC1)
12%
Quantitative PCR
12%
Cyclooxygenase-2 Expression
12%
Anthracyclines
11%
High Risk
11%
P53 Expression
11%
HER2 Status
11%
Distinct Subtypes
10%
Breast Cancer Patients
10%
Tissue Microarray
10%
Poor Prognosis
10%